QRG Capital Management Inc. Has $5.87 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

QRG Capital Management Inc. raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.9% in the 3rd quarter, Holdings Channel reports. The firm owned 16,380 shares of the biotechnology company’s stock after acquiring an additional 1,059 shares during the period. QRG Capital Management Inc.’s holdings in United Therapeutics were worth $5,870,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. LSV Asset Management raised its holdings in shares of United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after buying an additional 436,851 shares in the last quarter. Swedbank AB acquired a new position in United Therapeutics during the first quarter worth about $97,316,000. Canada Pension Plan Investment Board lifted its holdings in shares of United Therapeutics by 567.2% in the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after acquiring an additional 153,700 shares during the last quarter. Pacer Advisors Inc. boosted its stake in shares of United Therapeutics by 19.6% in the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after purchasing an additional 92,240 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of United Therapeutics by 49.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 276,531 shares of the biotechnology company’s stock valued at $88,089,000 after purchasing an additional 91,597 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $382.77 on Wednesday. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $382.95. The business’s 50-day moving average is $356.00 and its 200-day moving average is $318.81. The company has a market capitalization of $17.09 billion, a price-to-earnings ratio of 16.81, a P/E/G ratio of 1.08 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.38 earnings per share. Analysts anticipate that United Therapeutics Co. will post 25.44 EPS for the current year.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $328.39, for a total value of $1,182,204.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $42,690.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other United Therapeutics news, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $45,293.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $328.39, for a total transaction of $1,182,204.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $42,690.70. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 85,022 shares of company stock valued at $30,412,032 over the last ninety days. 11.90% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

UTHR has been the subject of several research reports. Bank of America dropped their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research note on Thursday, August 1st. HC Wainwright raised their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Oppenheimer boosted their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Argus increased their target price on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, LADENBURG THALM/SH SH boosted their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.